Repare shares jump 17.51% premarket after Gilead agrees to acquire RP-3467, boosting cash and shareholder payments.

Repare Therapeutics surged 17.51% in premarket trading following the announcement that Gilead Sciences agreed to acquire its Polθ ATPase inhibitor RP-3467 for $25 million upfront, with up to $5 million in additional payments tied to technology transfer milestones. The transaction boosted Repare’s cash reserves, directly increasing the estimated $2.20 per-share payment under its pending $30 million acquisition by XenoTherapeutics. The Gilead deal, described by Repare’s CEO as the third major portfolio transaction of the year, enhances the company’s value proposition ahead of the Xeno merger, which is expected to close with adjusted cash payments to shareholders based on Repare’s updated liquidity position. The combined impact of the two agreements and the strengthening cash position drove the sharp premarket rally.